Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase, J Am Soc Nephrol, vol.25, pp.675-680, 2014. ,
, Allo-Immune Membranous Nephropathy and Replacement Therapy antibodies, N Engl J Med, vol.346, pp.2053-2060, 2002.
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies, Lancet, vol.364, pp.1252-1259, 2004. ,
The molecular basis of Goodpasture and Alport syndromes: Beacons for the discovery of the collagen IV family, J Am Soc Nephrol, vol.15, pp.2514-2527, 2004. ,
Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: Role of nephrin, Transplantation, vol.73, pp.394-403, 2002. ,
Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders, Clin Appl Immunol Rev, vol.2, pp.241-253, 2002. ,
Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models, Mol Genet Metab, vol.68, pp.268-275, 1999. ,
Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction, Curr Pharm Biotechnol, vol.3, pp.349-360, 2002. ,
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease, Pediatrics, vol.114, pp.532-535, 2004. ,
The molecular basis of lysosomal storage diseases and their treatment, Biochem Soc Trans, vol.28, pp.150-154, 2000. ,
, Orphanet J Rare Dis, vol.5, 2010.
Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis, J Exp Med, vol.113, pp.899-920, 1961. ,
Human idiopathic membranous nephropathy-a mystery solved?, N Engl J Med, vol.361, pp.81-83, 2009. ,
Pathogenesis of membranous nephropathy: Recent advances and future challenges, Nat Rev Nephrol, vol.8, pp.203-213, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00919135
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, vol.361, pp.11-21, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00417718
Early-childhood membranous nephropathy due to cationic bovine serum albumin, N Engl J Med, vol.364, pp.2101-2110, 2011. ,
,
, Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study, MPS VI Phase 3 Study Group, vol.148, pp.533-539, 2006.
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP), J Inherit Metab Dis, vol.36, pp.373-384, 2013. ,
Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier, J Am Soc Nephrol, vol.20, 1929. ,
Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics, Eur J Pharmacol, vol.395, pp.95-101, 2000. ,
Human podocytes possess a stretch-sensitive, Ca2 +-activated K+ channel: Potential implications for the control of glomerular filtration, J Am Soc Nephrol, vol.15, pp.2981-2987, 2004. ,
Chinese hamster ovary cell-derived recombinant human acid alphaglucosidase in infantile-onset Pompe disease, J Pediatr, vol.149, pp.89-97, 2006. ,
Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration, Blood, vol.93, pp.2081-2088, 1999. ,
Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment, Nat Biotechnol, vol.26, pp.901-908, 2008. ,
Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor, J Am Soc Nephrol, vol.23, pp.1949-1954, 2012. ,
, , 2013030290.